Barclays Issues Pessimistic Forecast for Organon & Co. (NYSE:OGN) Stock Price

Organon & Co. (NYSE:OGN) had its price objective cut by stock analysts at Barclays from $26.00 to $24.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 56.91% from the company’s current price.

OGN has been the topic of a number of other reports. Morgan Stanley decreased their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.80.

Organon & Co. Price Performance

OGN stock opened at $15.30 on Friday. The firm has a 50 day moving average of $15.35 and a 200-day moving average of $17.45. The firm has a market capitalization of $3.94 billion, a P/E ratio of 3.03, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. As a group, sell-side analysts predict that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Institutional Trading of Organon & Co.

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Organon & Co. by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock worth $453,593,000 after acquiring an additional 218,165 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of Organon & Co. by 94,482.1% during the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Organon & Co. by 1.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock worth $147,634,000 after purchasing an additional 136,760 shares during the period. LSV Asset Management lifted its stake in Organon & Co. by 0.4% in the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock worth $112,274,000 after purchasing an additional 30,557 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Organon & Co. by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 4,260,218 shares of the company’s stock valued at $63,582,000 after buying an additional 12,110 shares during the period. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.